Aricept
Product Images NDC 54868-4245

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Aricept (NDC 54868-4245). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 5 mg Package Label (3952)

Aricept 5 mg film-coated tablets packaging label by Physicians Total Care, Inc. The label states that each tablet contains 5 mg of donepezil hydrochloride, with a total of 90 tablets in the container. It includes caution information regarding federal law and prescription use. The label also shows lot number, expiration date, and storage instructions.*

FDA Label Image

Image Of 10 mg Package Label (4245)

Aricept 10 mg tablet label from Physicians Total Care, Inc. The label specifies 90 tablets per bottle and identifies the active ingredient as donepezil hydrochloride. It includes warnings about federal law restrictions, directions to keep out of reach of children, storage instructions, lot number, and expiration date.*

FDA Label Image

Aricept-01 (Aricept 01)

Chemical structure of donepezil hydrochloride, the active ingredient in Aricept by Physicians Total Care, Inc. The structure shows a benzylpiperidine derivative with methoxy substituents and a chloride ion (HCl).*

FDA Label Image

Aricept-02 (Aricept 02)

A line graph depicting clinical changes in ADAS-cog scores from baseline over 24 weeks of drug treatment for Aricept 10 mg/day, Aricept 5 mg/day, and placebo groups. The y-axis represents change in ADAS-cog score, with positive values indicating clinical improvement and negative indicating clinical decline. Data points include error bars reflecting standard error.*

FDA Label Image

Aricept-03 (Aricept 03)

A line graph illustrating the cumulative percentage of patients against change from baseline in ADAS-cog scores for three treatment groups: Aricept 10 mg/day, Aricept 5 mg/day, and placebo. The graph shows curves for each group, with arrows indicating 7 points, 4 points, and no change thresholds. A legend presents percentage changes in ADAS-cog for each treatment group.*

FDA Label Image

Aricept-04 (Aricept 04)

A bar chart comparing the percentage of patients with different CIBIC-plus ratings for Aricept 10 mg/day, Aricept 5 mg/day, and placebo. The categories on the horizontal axis range from Markedly Improved to Markedly Worse, with the vertical axis showing the percentage of patients from 0 to 50%.*

FDA Label Image

Aricept-05 (Aricept 05)

A line graph showing the effect of Aricept 10 mg/day, Aricept 5 mg/day, and placebo on ADAS-cog change from baseline over 15 weeks. The x-axis represents weeks of drug treatment and placebo, and the y-axis indicates mean change from baseline with error bars. Aricept groups show clinical improvement, while placebo shows decline.*

FDA Label Image

Aricept-06 (Aricept 06)

A line graph showing cumulative percentage of patients over change from baseline in ADAS-cog scores. It compares Aricept 10 mg/day, Aricept 5 mg/day, and placebo treatment groups, illustrating cognitive score changes at multiple points with a legend and a summary table of percentage change in ADAS-cog at specified time intervals.*

FDA Label Image

Aricept-07 (Aricept 07)

A bar chart comparing the percentage of patients by CIBIC-plus rating categories for Aricept 10 mg/day, Aricept 5 mg/day, and placebo groups. The x-axis shows CIBIC-plus ratings from Markedly Improved to Markedly Worse, and the y-axis indicates the percentage of patients in each category.*

FDA Label Image

Aricept-08 (Aricept 08)

Line graph depicting SIB change from baseline over six months of drug treatment, comparing Aricept 10 mg/day and placebo. The graph shows clinical improvement on the positive Y-axis and clinical decline on the negative Y-axis, with Aricept indicating improvement and placebo showing decline over time.*

FDA Label Image

Aricept-09 (Aricept 09)

A cumulative percentage line graph comparing the effects of Aricept 10 mg/day versus placebo on SIB (Severe Impairment Battery) change from baseline in patients. The x-axis represents the SIB change from baseline, and the y-axis shows the cumulative percentage of patients. Two lines, one for Aricept and one for placebo, illustrate the differences in patient outcomes over the measured change range.*

FDA Label Image

Aricept-10 (Aricept 10)

A line graph showing the mean change from baseline in ADCS-ADL scores over six months of drug treatment for Aricept 10 mg/day versus placebo. The y-axis represents clinical improvement or decline, with Aricept maintaining higher scores compared to placebo, which shows greater decline over time.*

FDA Label Image

Aricept-11 (Aricept 11)

A line graph displaying cumulative percentage of patients on the vertical axis and ADCS-ADL change from baseline on the horizontal axis. It compares Aricept 10 mg/day versus placebo, showing the progression over the measured range.*

FDA Label Image

Aricept-12 (Aricept 12)

A line graph showing the change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale (SIB) scores over 24 weeks of drug treatment for Aricept at 10 mg/day and 23 mg/day. The graph includes two lines with error bars indicating mean values and variability, illustrating clinical improvement or decline over time.*

FDA Label Image

Aricept-13 (Aricept 13)

A line graph depicting the cumulative percentage of patients on the vertical axis versus SIB (Severe Impairment Battery) change from baseline on the horizontal axis. Two lines represent patients taking Aricept at 23 mg/day and 10 mg/day doses, showing the distribution of SIB score changes from baseline for each group.*

FDA Label Image

Aricept-14 (Aricept 14)

A bar chart showing the CIBIC-plus rating distribution of patients treated with Aricept at 23 mg/day and 10 mg/day doses. The x-axis categorizes patient outcomes from Markedly Improved to Markedly Worse, while the y-axis shows percentage of patients. The chart compares the percentage of patients in each category for the two dosages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.